GLUE
Monte Rosa Therapeutics Inc
NASDAQ: GLUE · HEALTHCARE · BIOTECHNOLOGY
$20.39
+5.37% today
Updated 2026-05-06
Market cap
$1.50B
P/E ratio
—
P/S ratio
12.16x
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$4 – $26
Volume
1.1M
Monte Rosa Therapeutics Inc (GLUE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $75.62M | $123.67M |
| Revenue growth (YoY) | — | — | — | — | — | — | +63.5% |
| Cost of revenue | $72000.00 | $537000.00 | $2.13M | $8.56M | $6.22M | $8.12M | $8.36M |
| Gross profit | $-72000.00 | $-537000.00 | $-2.13M | $-8.56M | $-6.22M | $67.50M | $115.32M |
| Gross margin | — | — | — | — | — | 89.3% | 93.2% |
| R&D | $7.35M | $23.47M | $57.16M | $85.06M | $105.05M | $121.56M | $141.50M |
| SG&A | $644000.00 | $4.00M | $15.73M | $27.32M | $32.04M | $35.17M | $36.38M |
| Operating income | $-7.99M | $-28.01M | $-72.88M | $-112.38M | $-143.31M | $-81.11M | $-54.21M |
| Operating margin | — | — | — | — | — | -107.3% | -43.8% |
| EBITDA | $-7.67M | $-27.47M | $-70.75M | $-108.64M | $-137.09M | $-72.99M | $-45.85M |
| EBITDA margin | — | — | — | — | — | -96.5% | -37.1% |
| EBIT | $-7.74M | $-28.01M | $-72.88M | $-112.38M | $-143.31M | $-81.11M | $-54.21M |
| Interest expense | $1000.00 | $9000.00 | $1.08M | $3.76M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-8.02M | $-35.88M | $-73.96M | $-108.50M | $-135.35M | $-72.70M | $-38.63M |
| Net income growth (YoY) | — | -347.5% | -106.1% | -46.7% | -24.7% | +46.3% | +46.9% |
| Profit margin | — | — | — | — | — | -96.1% | -31.2% |